Julian Downward

The Francis Crick Institute — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

114h-index62.3kcitations664works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(108), PI3K/AKT/mTOR signaling in cancer(92), Lung Cancer Treatments and Mutations(76), Cancer-related Molecular Pathways(55), Cancer Immunotherapy and Biomarkers(52)

Publications663 total

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma
2025Open Access
Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells
2025Open Access
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Science·2025· 1 citedOpen Access
Corrigendum to RAS interaction with PI3K p110α is required for tumor-induced angiogenesis
Journal of Clinical Investigation·2025Open Access
Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy
2025Open Access
RAS–p110α signalling in macrophages is required for effective inflammatory response and resolution of inflammation
eLife·2025· 1 citedOpen Access
Author response: RAS–p110α signalling in macrophages is required for effective inflammatory response and resolution of inflammation
2025Open Access
Tumor-Infiltrating Clonal Hematopoiesis
New England Journal of Medicine·2025· 48 citedOpen Access
Author Correction: Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110α
Scientific Reports·2025Open Access
Figure 5 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Data from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 4 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Figure 3 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S1 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Figures S1-S10 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
Supplementary Table S2 from Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma
2025Open Access
page 1 of 34Next →

Frequent Co-authors

Patricia H. Warne(8), L. Miguel Martins(5), Almut Schulze(5), Gordon Stamp(4), Charles Swanton(4), Michael D. Waterfield(4), Pablo Rodriguez‐Viciana(4), Peter J. Parker(4), David Endesfelder(3), Zoltán Szállási(3), Nicholas F. Totty(3), Kerstin Lehmann(3), Emma Nye(3), Barbara Nicke(3), Tencho Tenev(3), Nicholas R. Lemoine(3), Michael Howell(3), Kristina Klupsch(3), Andrew J. Rowan(2), Eva Grönroos(2)